Nanotechnology based platforms for survivin targeted drug discovery

Bibliography

• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326(Pt 1):1-16
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 2003;3:46-54
   PubMed Web of Science ®Google Scholar
• Mita AC, Mita MM, Nawrocki ST, Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5
   PubMed Web of Science ®Google Scholar
• Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007;27:17-28
   PubMed Web of Science ®Google Scholar
• Altieri DC. Targeting survivin in cancer. Cancer Lett 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011;16:485-94
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: A multifaceted dragon. Med Res Rev 2012. [Epub ahead of print]
   Google Scholar
• Talbot DC, Ranson M, Davies J, Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010;16:6150-8
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Berntsen A, Hadrup SR, Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010;12:721-34
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008;31:771-80
   PubMed Web of Science ®Google Scholar
• Verma IM, Somia N. Gene therapy -- promises, problems and prospects. Nature 1997;389:239-42
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Shen WP, Kanwar RK, Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-52
   PubMed Web of Science ®Google Scholar
• Baratchi S, Kanwar RK, Cheung CH, Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol 2010;227:120-32
   PubMed Web of Science ®Google Scholar
• Baratchi S, Kanwar RK, Kanwar JR. Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. J Neuroimmunol 2011;233:18-28
   PubMed Web of Science ®Google Scholar
• Baratchi S, Kanwar RK, Kanwar JR. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS ONE 2011;6:e15865
   PubMedGoogle Scholar
• Cheung CH, Sun X, Kanwar JR, A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int 2010;10:36
   PubMed Web of Science ®Google Scholar
• Grossman D, Kim PJ, Schechner JS, Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98:635-40
   PubMed Web of Science ®Google Scholar
• O'Connor DS, Grossman D, Plescia J, Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000;97:13103-7
   PubMed Web of Science ®Google Scholar
• Peng XC, Yang L, Yang LP, Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant. J Exp Clin Cancer Res 2008;27:46
   PubMed Web of Science ®Google Scholar
• Shan Y, Wang C, Yang L, Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration. J Biosci 2010;35:209-16
   PubMed Web of Science ®Google Scholar
• Pan L, Peng XC, Leng F, Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol 2011;137:19-28
   PubMed Web of Science ®Google Scholar
• Yu DD, Wang CT, Shi HS, Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res 2010;29:46
   PubMedGoogle Scholar
• Seth S, Matsui Y, Fosnaugh K, RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011;19:928-35
   Google Scholar
• Kenny GD, Kamaly N, Kalber TL, Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011;149:111-16
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Zhang X, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650-6
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhan G, Ye D, MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Liu X, Ryland L, Yang J, Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010;116:4192-201
   PubMed Web of Science ®Google Scholar
• Jatzkewitz H. Incorporation of physiologically-active substances into a colloidal blood plasma substitute. I. Incorporation of mescaline peptide into polyvinylpyrrolidone. Hoppe Seylers Z Physiol Chem 1954;297:149-56
   PubMedGoogle Scholar
• Zhang L, Gao X, Men K, Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A. Int J Nanomedicine 2011;6:2419-27
   PubMed Web of Science ®Google Scholar
• Yan Y, Jiang J, Cao M, Survivin antisense oligodeoxynucleotide mediated by polyethyleneimine enhances sensitivity to chemotherapy in SMMC-7721,a human hepatocelluar carcinoma cell line. J Jinan Univ 2007;28:147-51
   Google Scholar
• Wu F, Huang G, Jiang J, Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu. J S Med Univ 2009;29:2251-4
   Google Scholar
• Bhattacharyya SS, Paul S, and Khuda-Bukhsh AR Encapsulated plant extract (Gelsemium sempervirens) poly (lactide-co-glycolide) nanoparticles enhance cellular uptake and increase bioactivity in vitro. Exp Biol Med (Maywood) 2010;235:678-88
   PubMed Web of Science ®Google Scholar
• Paul S, Bhattacharyya SS, Boujedaini N, Anticancer Potentials of Root Extract of Polygala senega and Its PLGA Nanoparticles-Encapsulated Form. Evid Based Complement Alternat Med 2011;2011: Article ID 517204
   Google Scholar
• Liu S, Sun X, Nie Y, Preparation and characteristics of chitosan nanoparticles carrying gene in vitro. West China J Pharm Sci 2004;19:409-11
   Google Scholar
• Yu L, Zhang Y, Song C, Preparation and characterization of PEGylated chitosan/survivin siRNA complex. China J Mod Med 2009;19:1130-33
   Google Scholar
• Kanwar JR, Mahidhara G, and Kanwar RK Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov Today 2011;16:188-202
   PubMed Web of Science ®Google Scholar
• Wang Y, Han Y, Yang Y, Effect of interaction of magnetic nanoparticles of Fe3O4 and artesunate on apoptosis of K562 cells. Int J Nanomed 2011;6:1185-92
   PubMed Web of Science ®Google Scholar
• Wang J, Chen B, Cheng J, Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomed 2011;6:1027-34
   PubMed Web of Science ®Google Scholar
• Cao Z, Sun Y, Zhu Y, Construction of magnetic small interfering RNA nanoparticles and effects of its transfection on silencing survivin gene expression and inducing human bladder cancer cell apoptosis. China J Mod Med 2008;18:385-90
   Google Scholar
• Medarova Z, Pham W, Farrar C, In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13:372-7
   PubMed Web of Science ®Google Scholar
• Peng J, He X, Wang K, An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells. Nanomedicine 2006;2:113-20
   PubMed Web of Science ®Google Scholar
• Medina SH, El-Sayed MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009;109:3141-57
   PubMed Web of Science ®Google Scholar
• Yao H, Yue S, Jin Y, Construction of survivin antisense oligodeoxynucleotide polyamidoamine carrier and its influence on apoptosis of hepatic cancer cells. Chin J Cancer Biother 2007;14:540-44
   Google Scholar
• Yao H, YUE S, Jin Y, Anti-tumor and anti-angiogenesis effects of survivin antisense oligodeoxynucleo-tide delivered by polyamidoamine dendrimer on subcutaneously-transplanted hepatic cancer in nude mice. Chin J Cancer Biother 2008;15:36-40
   Google Scholar
• Li Z, Huang Z, Cui D, Polyamidoamine dendrimer-mediated survivin antisense oligonucleotide inhibits the growth of subcutaneously transplanted colorectal cancer in nude mice. J South Med Univ 2008;28:1935-8
   Google Scholar
• Liu X, Huang H, Wang J, Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011;82:17-23
   PubMed Web of Science ®Google Scholar
• Pan B, Cui D, Sheng Y, Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007;67:8156-63
   PubMed Web of Science ®Google Scholar
• Nel A, Xia T, Madler L, Toxic potential of materials at the nanolevel. Science 2006;311:622-7
   PubMed Web of Science ®Google Scholar
• Arora S, Rajwade JM, Paknikar KM. Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol 2012;258:151-65
   PubMed Web of Science ®Google Scholar